Anafranil (clomipramine) is primarily indicated for the treatment of obsessive-compulsive disorder (OCD). It has a well-established evidence base for reducing the frequency and intensity of intrusive thoughts and compulsive behaviors in adults and in some pediatric populations when clinically appropriate. Clinicians often reserve Anafranil for patients who have not responded to selective serotonin reuptake inhibitors (SSRIs) or when a tricyclic antidepressant is considered suitable after weighing benefits and risks.
Beyond OCD, Anafranil may be used in some cases to treat major depressive disorder, panic disorder, and certain chronic pain syndromes, though these uses are less common and typically guided by specialist judgment. Its broad effects on serotonin and norepinephrine pathways contribute to mood regulation and reduction in anxiety-driven compulsions. Decisions to use Anafranil should be individualized, based on symptom severity, prior treatment history, comorbidities, and tolerability.
Dosing of Anafranil must be individualized and titrated slowly to minimize side effects. Adults typically start at low doses—often 25 mg once daily or 10–25 mg at bedtime—to assess tolerability. For OCD, doses are usually increased gradually over weeks, commonly reaching a target range of 100–250 mg per day depending on response and tolerability. For depression, some regimens may reach similar ranges but always under careful supervision. Divide doses when total daily dose exceeds 100 mg to reduce anticholinergic and cardiovascular side effects.
For pediatric use in OCD, clinicians generally start at lower doses and increase cautiously. Treatment in adolescents requires pediatric expertise because children can be more sensitive to adverse effects and require close monitoring for behavioral changes. Elderly patients or those with hepatic impairment often need lower starting doses and slower titration due to increased sensitivity and altered drug metabolism.
Administration tips: take Anafranil with food if gastrointestinal upset occurs, avoid abrupt discontinuation to prevent withdrawal symptoms, and schedule follow-ups to monitor efficacy and adverse effects. Laboratory tests and ECGs may be warranted before and during treatment in patients with cardiac risk factors or high doses.
Anafranil carries several important precautions. It can increase suicidal thoughts or behaviors in children, adolescents, and young adults, particularly during early treatment or dose changes; patients starting the drug require close monitoring for worsening depression, suicidal ideation, or unusual changes in behavior. Older adults are at higher risk for anticholinergic effects, orthostatic hypotension, falls, and cardiac conduction abnormalities.
Cardiac evaluation may be necessary before initiating therapy in patients with known heart disease, conduction abnormalities, or significant risk factors. Anafranil can prolong the QT interval in susceptible individuals, especially when combined with other QT-prolonging drugs. Monitor for signs of arrhythmia, syncope, or palpitations.
Serotonin syndrome is a potentially life-threatening condition when Anafranil is combined with other serotonergic agents (SSRIs, SNRIs, triptans, MDMA, certain opioids). Be vigilant for symptoms such as agitation, hyperreflexia, autonomic instability, hyperthermia, and neuromuscular abnormalities. If serotonin syndrome is suspected, discontinue serotonergic drugs and seek immediate medical attention.
Anafranil is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) and for at least 14 days after stopping an MAOI, due to risk of severe and potentially fatal interactions, including serotonin syndrome. Conversely, avoid initiating an MAOI for at least 14 days after discontinuing Anafranil. Co-administration with pimozide and certain other drugs known to cause QT prolongation is generally contraindicated.
Other contraindications include known hypersensitivity to clomipramine or any tricyclic antidepressant, and situations where its anticholinergic or cardiac effects would pose excessive risk—such as recent myocardial infarction, uncontrolled narrow-angle glaucoma, or severe urinary retention. Pregnancy and breastfeeding require risk-benefit discussions; Anafranil is not an absolute contraindication in pregnancy, but alternative treatments may be preferred in many cases.
Common side effects of Anafranil stem from its anticholinergic, antihistaminic, and alpha-adrenergic blocking properties. Patients frequently report dry mouth, constipation, blurred vision, urinary hesitancy, and sedation. Weight gain and increased appetite may occur with longer-term use. Many of these effects lessen with time or dosing adjustments.
Cardiovascular side effects include orthostatic hypotension, tachycardia, and, less commonly, arrhythmias due to altered cardiac conduction. Sexual dysfunction—reduced libido, delayed orgasm, or erectile dysfunction—is also reported and can affect adherence. Rare but serious effects include seizures (especially at higher doses or in predisposed individuals), severe anticholinergic toxicity, and blood dyscrasias. Any sudden mood changes, suicidal thoughts, chest pain, severe dizziness, or fainting should prompt immediate medical attention.
Anafranil interacts with many medications. Concomitant use with MAOIs is dangerous and contraindicated. Combining Anafranil with SSRIs or SNRIs increases the risk of serotonin syndrome; fluoxetine and paroxetine can also raise Anafranil plasma concentrations through CYP2D6 inhibition, heightening toxicity risk. If such combinations are necessary, dose adjustments and close monitoring are required.
Because Anafranil may prolong QT interval, combining it with other QT-prolonging drugs (certain antipsychotics, macrolide antibiotics like erythromycin, some antiarrhythmics) increases arrhythmia risk. Additive anticholinergic effects can occur with antihistamines, antipsychotics, and some anti-Parkinson medications, worsening dry mouth, constipation, urinary retention, and confusion. CNS depressants including benzodiazepines and alcohol can intensify sedation; caution and dose adjustments are advised. Discuss all prescription, over-the-counter medicines, and supplements with your healthcare provider to avoid harmful interactions.
You may also explore Torsemide information while considering suitable treatment alternatives.If you miss a dose of Anafranil, take it as soon as you remember unless it is close to the time for your next scheduled dose. Do not double up doses to make up for a missed one. Repeated missed doses can reduce clinical benefit and increase relapse risk; if you miss several doses in a row, contact your clinician before resuming, as they may recommend restarting at a lower dose and titrating up to reduce withdrawal or side effects.
Overdose of Anafranil is a medical emergency. Symptoms of overdose can include severe drowsiness, coma, confusion, seizures, rapid or irregular heartbeat, low blood pressure, respiratory depression, and anticholinergic signs such as dilated pupils and high body temperature. Cardiotoxicity (arrhythmias and conduction disturbances) is a major cause of morbidity and mortality in tricyclic antidepressant overdose.
If an overdose is suspected, seek emergency medical help immediately. Management focuses on rapid stabilization: airway support, activated charcoal if within appropriate time frame and patient is protected airway-wise, continuous cardiac monitoring, intravenous fluids for hypotension, sodium bicarbonate therapy for wide-complex ventricular arrhythmias or severe cardiotoxicity, and benzodiazepines for seizures. There is no routine role for dialysis. Early involvement of a poison control center and critical care specialists improves outcomes.
Store Anafranil at room temperature away from excess heat, moisture, and direct sunlight. Keep the medication in its original container, tightly closed, and out of reach of children and pets. Do not use if tablets appear discolored or damaged. Properly dispose of unused or expired medication according to local guidelines or pharmacy take-back programs—do not flush medications down the toilet unless instructed.
Handle with caution: because Anafranil can cause drowsiness and impair judgment, avoid driving or operating heavy machinery until you understand how the drug affects you. Avoid alcohol and other sedating substances that can exacerbate impairment.
In the United States, Anafranil is a prescription medication and should be used under medical supervision. Sunshine Pharmacy offers a legal and structured solution for acquiring Anafranil without a formal paper prescription by providing an online clinical consultation and pharmacist review process. Through Sunshine Pharmacy’s platform, eligible patients complete a secure medical assessment, and licensed clinicians evaluate suitability before authorizing medication. This service is intended to streamline access while maintaining safety checks, dosing guidance, and follow-up.
Important: availability, shipping, and eligibility depend on state and federal regulations. Sunshine Pharmacy complies with applicable laws and will not dispense Anafranil to individuals for whom the medication is unsafe or where local rules prohibit remote prescribing. Always verify pharmacy credentials and ensure you receive clear instructions on dosing, monitoring, and access to clinical support after purchase.
Before starting Anafranil, inform your healthcare provider about all medical conditions, especially cardiac disease, history of seizures, glaucoma, bladder problems, enlarged prostate, thyroid disease, liver disease, and pregnancy or breastfeeding. Report all medications, supplements, and illicit substances to avoid dangerous interactions. Pregnant or nursing individuals should discuss risks and benefits; clomipramine can have fetal and neonatal effects and may be detectable in breast milk.
Monitor closely for mood changes, worsening depression, or emergence of suicidal ideation, particularly during the first months of treatment or when doses change. Keep regular follow-up visits and seek immediate help if you experience chest pain, fainting, severe dizziness, severe constipation, urinary retention, or signs of serotonin syndrome. Avoid abrupt discontinuation; a gradual taper supervised by a clinician reduces withdrawal risk including dizziness, irritability, and flu-like symptoms.
Patients should take Anafranil exactly as prescribed. Expect a gradual onset of benefit—symptom improvement may take several weeks and full effects can require longer. Maintain a medication diary to track symptom changes and side effects, and bring this information to follow-up appointments. Do not share Anafranil with others, and keep it in a secure location. If you plan to stop therapy, consult your prescribing clinician to design a tapering schedule to minimize withdrawal effects.
Lifestyle considerations: maintain a regular sleep schedule, avoid excessive alcohol, and discuss contraception and pregnancy planning with your provider if applicable. If you experience bothersome side effects, do not stop the medication abruptly—contact your prescriber to discuss dose adjustments or alternative treatments. For urgent concerns—severe allergic reactions, chest pain, fainting, seizures, or thoughts of self-harm—seek emergency medical care immediately.
Anafranil is the brand name for clomipramine, a tricyclic antidepressant (TCA). It is primarily prescribed for obsessive-compulsive disorder (OCD) and is also used for major depressive disorder, certain anxiety disorders, and chronic pain or off-label indications. It works by affecting neurotransmitters in the brain, especially serotonin.
Anafranil blocks the reuptake of serotonin and, to a lesser extent, norepinephrine, increasing their levels in the synaptic cleft. It also has effects on various receptors (anticholinergic, antihistaminic, and alpha-adrenergic), which contribute to both therapeutic actions and side effects.
For OCD symptoms, some improvement may be noticed within 2–4 weeks, but meaningful benefit often takes 6–12 weeks. For depressive symptoms, improvements may appear within 2–6 weeks. Full therapeutic effect can take longer and depends on dose, adherence, and individual response.
Common side effects include dry mouth, constipation, blurred vision, drowsiness or sedation, weight gain, increased heart rate, dizziness, and sexual dysfunction. Many side effects are due to anticholinergic and antihistaminic actions.
Serious risks include cardiac arrhythmias (prolonged QT interval), severe orthostatic hypotension, seizures (especially at higher doses or with predisposition), serotonin syndrome (if combined with other serotonergic drugs), and severe allergic reactions. Seek urgent care for chest pain, fainting, rapid/irregular heartbeat, severe confusion, high fever with muscle rigidity, or signs of severe allergic reaction.
Dosing starts low and is increased gradually. For OCD, adults often start at a low dose and titrate to therapeutic ranges commonly between 100–250 mg/day, sometimes higher under close supervision. For depression doses may be lower. Individualized dosing is necessary; a clinician will adjust based on response and tolerability.
Anafranil is sometimes prescribed for pediatric OCD and has evidence of efficacy, but dosing and monitoring must be done by a specialist. Children can be more sensitive to side effects; risks and benefits should be carefully weighed and parents/caregivers closely monitor for behavioral changes including suicidal thoughts.
Use during pregnancy requires careful consideration. Clomipramine may carry risks (e.g., neonatal adaptation syndrome) and should be used when benefits justify potential fetal risk. It is excreted in breast milk; breastfeeding while on Anafranil can expose the infant to the drug. Discuss risks and alternatives with an obstetrician and psychiatrist.
Do not stop abruptly. Gradual tapering under medical supervision reduces withdrawal symptoms such as dizziness, nausea, irritability, insomnia, and return of anxiety or depressive symptoms. Taper schedules vary depending on dose and duration of therapy.
Anafranil interacts with many drugs: other antidepressants (especially MAOIs and SSRIs), antipsychotics, certain antiarrhythmics, benzodiazepines, opioids, antihypertensives, anticholinergics, and medications that affect CYP enzymes. Combining with other serotonergic drugs increases serotonin syndrome risk. Always tell your clinician about all medications, supplements, and herbal products.
TCA overdose can be life-threatening, causing severe cardiac arrhythmias, CNS depression, seizures, and hypotension. Emergency care is essential. Management includes activated charcoal if appropriate, cardiac monitoring, supportive care, seizure control, sodium bicarbonate for cardiac toxicity, and intensive monitoring in an ICU.
Yes. Common sexual side effects include decreased libido, erectile dysfunction, delayed ejaculation, and anorgasmia. These are related to serotonergic and anticholinergic effects and may persist while on therapy.
Weight gain is a possible side effect for some people, likely related to antihistaminic effects, increased appetite, and metabolic changes. Monitoring weight and lifestyle counseling can help manage this.
Anafranil can cause sedation, drowsiness, slowed reaction time, and impaired concentration, especially when starting treatment or after dose increases. Avoid driving or operating machinery until you know how it affects you. These effects may diminish over time.
Alcohol can increase sedation, impair judgment, and exacerbate side effects such as dizziness and drowsiness. Combined use is not recommended; discuss any alcohol use with your clinician.
Baseline and periodic monitoring may include ECG (especially in older adults or those with cardiac risk), blood pressure (including orthostatic checks), weight, metabolic parameters where indicated, assessment for suicidal ideation, and evaluation of side effects. Drug levels are not routinely measured but may be used in special circumstances.
Take the missed dose as soon as remembered unless it is close to the next scheduled dose. Do not double up doses. If in doubt, consult your prescribing clinician or pharmacist for guidance.
Yes. Abrupt discontinuation can lead to withdrawal-like symptoms: dizziness, nausea, headache, irritability, sleep disturbances, and sensory disturbances. Taper gradually under medical supervision to minimize these effects.
Duration depends on indication and individual response. For OCD, long-term treatment (often many months to years) may be recommended to prevent relapse. For depression, continuation for several months after remission is common. Decisions are individualized with the prescriber.
Reliable sources include your prescribing clinician, pharmacists, official drug labeling, national health services, and peer-reviewed medical literature. Use caution with unverified internet sources and discuss questions with your healthcare team.
Both are TCAs and share anticholinergic and cardiotoxic risks. Amitriptyline is commonly used for depression and neuropathic pain; clomipramine (Anafranil) has stronger serotonergic activity and is more effective for OCD. Amitriptyline may be more sedating and used at lower doses for pain, while Anafranil’s potency against OCD distinguishes it clinically.
Yes. Clomipramine has more robust efficacy for OCD compared with many other TCAs, including imipramine, due to its stronger serotonin reuptake inhibition. Imipramine is better known for depression and has less evidence in OCD.
Nortriptyline is a secondary amine TCA with a generally more favorable anticholinergic profile and often fewer sedative effects than clomipramine. For OCD specifically, Anafranil is typically preferred; for tolerability in depression, nortriptyline may be easier to tolerate for some patients.
All TCAs carry cardiac risk, especially in overdose or with existing heart disease. Desipramine tends to have less anticholinergic activity but can still prolong cardiac conduction. Clomipramine’s serotonergic activity and anticholinergic effects require careful cardiac monitoring similar to other TCAs, particularly in vulnerable patients.
Doxepin is highly antihistaminic and can be very sedating; it’s sometimes used for insomnia at low doses. Clomipramine has stronger serotonergic action and is preferred for OCD; doxepin may cause more pronounced sedation and weight gain in some patients.
All TCAs lower seizure threshold to some degree, but the risk varies with dose and individual susceptibility. Clomipramine can provoke seizures, particularly at higher doses or with interactions; clinicians weigh seizure risk when choosing and dosing TCAs.
TCAs as a class have significant overdose toxicity (cardiac arrhythmias, hypotension, CNS depression). Clomipramine carries similar serious overdose risks as other TCAs; the specific risk may vary by dose and formulation, so cautious prescribing and limiting quantities for at-risk patients are common practices.
Clomipramine is often effective when SSRIs or other TCAs fail, due to its potent serotonergic effect; it is considered a key option for treatment-resistant OCD. However, its side-effect burden and safety profile require careful monitoring.
Many interactions are shared across TCAs (MAOI contraindications, additive anticholinergic or sedative effects, QT-prolonging drugs). Clomipramine’s strong serotonergic activity increases the risk of serotonin syndrome when combined with other serotonergic agents (e.g., SSRIs, SNRIs, triptans), so clinicians are particularly cautious about such combinations.
Anafranil is typically available in oral tablets with flexible dosing for titration. Some TCAs have extended-release formulations or lower-dose preparations for insomnia/analgesia (e.g., amitriptyline at low doses). Choice of TCA often depends on indication, side-effect profile, and patient-specific factors.
In elderly patients, clinicians often favor TCAs with fewer anticholinergic effects, like nortriptyline, due to risks of confusion, urinary retention, and falls. Clomipramine’s anticholinergic and sedative properties make it less ideal in many older adults unless benefits clearly outweigh risks.
Combining TCAs is generally avoided due to additive side effects, increased cardiotoxicity, and complex interactions. If multiple antidepressant strategies are needed, clinicians more commonly combine a TCA with a non-TCA agent under close supervision rather than two TCAs.
Choice depends on the primary diagnosis (OCD favors clomipramine), side-effect tolerability, cardiac and seizure risk, age, comorbidities, potential drug interactions, and prior treatment response. Shared decision-making and specialist input are valuable for complex cases.
